Nicotinamide (Nam) phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme in mammalian NAD synthesis, catalyzing nicotinamide mononucleotide (NMN) formation from Nam and 5-phosphoribosyl 1-pyrophosphate (PRPP). NAMPT has also been described as an adipocytokine visfatin with a variety of actions, although physiological significance of this protein remains unclear. It has been proposed that possible actions of visfatin are mediated through the extracellular formation of NMN. However, we did not detect NMN in mouse blood plasma, even with a highly specific and sensitive liquid chromatography/tandem mass spectrometry. Furthermore, there is no or little ATP, the activator of NAMPT, in extracellular spaces. We thus questioned whether visfatin catalyzes the in situ formation of NMN under such extracellular milieus. To address this question, we here determined Km values for the substrates Nam and PRPP in the NAMPT reaction without or with ATP using a recombinant human enzyme and found that 1 mM ATP dramatically decreases Km values for the substrates, in particular PRPP to its intracellular concentration. Consistent with the kinetic data, only when ATP is present at millimolar levels, NAMPT efficiently catalyzed the NMN formation at the intracellular concentrations of the substrates. Much lower concentrations of Nam and almost the absence of PRPP and ATP in the blood plasma suggest that NAMPT should not efficiently catalyze its reaction under the extracellular milieu. Indeed, NAMPT did not form NMN in the blood plasma. From these kinetic analyses of the enzyme and quantitative determination of its substrates, activator, and product, we conclude that visfatin does not participate in NMN formation under the extracellular milieus. Together with the absence of NMN in the blood plasma, our conclusion does not support the concept of “NAMPT-mediated systemic NAD biosynthesis.” Our study would advance current understanding of visfatin physiology.
Citation: Hara N, Yamada K, Shibata T, Osago H, Tsuchiya M (2011) Nicotinamide Phosphoribosyltransferase/Visfatin Does Not Catalyze Nicotinamide Mononucleotide Formation in Blood Plasma. PLoS ONE 6(8): e22781. https://doi.org/10.1371/journal.pone.0022781
Editor: Matej Oresic, Governmental Technical Research Centre of Finland, Finland
Received: February 16, 2011; Accepted: July 7, 2011; Published: August 3, 2011
Copyright: © 2011 Hara et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by a Grant-in-Aid for Scientific Research (21580139). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
In mammalian cells, NAD is synthesized through the de novo pathway from tryptophan or salvage pathways from nicotinamide (Nam) and nicotinic acid (NA) . The salvage synthesis is initiated by the addition of a phosphoribosyl moiety from 5-phosphoribosyl 1-pyrophosphate (PRPP) to the respective precursors yielding the corresponding Nam and NA mononucleotides (NMN and NaMN) in the reactions catalyzed by the rate-limiting enzymes Nam phosphoribosyltransferase (NAMPT) and NA phosphoribosyltransferase (NAPRT), respectively (Fig. 1), using ATP as the activator –.
NaAD, NA adenine dinucleotide; NMNAT, NMN adenylyltransferase; NaMNAT, NaMN adenylyltransferase; NADsyn, NAD synthetase. Broken arrows indicate the possible extracellular pathway in NAD biosynthesis .
In addition to being an intracellular NAD synthetic enzyme, NAMPT, originally identified as pre-B cell colony enhancing factor , has also been described as a novel adipocytokine visfatin , with a potential link to obesity, type 2 diabetes, and inflammatory diseases –. However, because of markedly conflicting associations between visfatin and these diseases in subsequent clinical studies , , the physiological significance of this protein remains largely unclear.
Revollo et al. have proposed that extracellular visfatin acts through “NAMPT-mediated systemic NAD biosynthesis” , . In this proposal, it is hypothesized that Nam in blood circulation is converted to NMN by visfatin, and the resulting NMN is distributed to tissues, transported to the inside of cells, and converted to NAD to elicit reported biological effects. Subsequent studies have also suggested possible extracellular conversion of Nam to NMN by visfatin and novel functions of the resultant NMN , . However, extracellular spaces are thought to contain little or no ATP . We thus questioned whether visfatin is enzymatically active under such extracellular milieus. Indeed, the in situ formation of NMN by visfatin under the extracellular environments has not been directly investigated , , although enzyme activity of the secreted NAMPT was demonstrated under an in vitro condition with a sufficiently high concentration of ATP .
To address our question, we first determined Km values for the substrates Nam and PRPP in the NAMPT reaction using a recombinant human enzyme in the absence or presence of ATP. We then evaluated NAMPT activity under the intra- and extracellular milieus, based on kinetic parameters as well as the actual intra- and extracellular concentrations of the substrates and ATP we obtained in this study. We finally determined directly whether NAMPT catalyzes the in situ formation of NMN in mouse blood plasma. Our findings reveal that visfatin does not efficiently catalyze its reaction under the extracellular milieus.
Materials and Methods
[Carbonyl-14C]Nam (50 mCi/mmol) and [carboxyl-14C]NA (50 mCi/mmol) were purchased from American Radiolabeled Chemical Inc. (St. Louis, MO, USA). ATP, PRPP, and firefly luciferase and luciferin were purchased from Oriental Yeast (Tokyo, Japan), Sigma (St. Louis, MO, USA), and Wako Pure Chemical Industries (Osaka, Japan), respectively.
Expression of wild-type human NAMPT and wild-type and mutant human NAPRT
Recombinant NAMPT and NAPRT were obtained as described previously . The vector used to express mutant NAPRT, in which His-213 is replaced by Asn, was produced using a pET22b plasmid vector carrying wild-type NAPRT  and primers 5′-C GGG ACC CTG GCC aac TCC TTC GTC AC-3′ and 5′-GT GAC GAAGGA gtt GGC CAG GGT CCC G-3′, where the altered codon is indicated by lower-case italics. The mutant enzyme was expressed and purified as described previously .
NAMPT and NAPRT assays
Enzyme preparations were incubated with PRPP and [14C]Nam (50 mCi/mmol) or [14C]NA (50 mCi/mmol) with a standard reaction mixture (30 µl) containing 50 mM Tris-Cl− (pH 7.5), 10 mM MgCl2, 2.5 mM dithiothreitol (DTT), and 1.5 µg bovine serum albumin (BSA) in the presence or absence of specific concentrations of ATP. After incubating at 37°C for a given time, the reaction was boiled for 60 sec, and NMN and NaMN formed were separated by thin layer chromatography and quantified as described previously . For kinetic analyses, enzymes were incubated with specific concentrations of PRPP together with Nam or NA in a standard reaction mixture with or without ATP at 37°C. The initial velocity was plotted against the concentration of the substrate. The curves were fitted using the non-linear regression method (DeltaGraph 5), from which the Km and Vmax for each reaction were derived.
Preparation of mouse blood plasma
The protocol of blood plasma preparation was approved by the ethical committee for animal experiments of Shimane University (Permit Numbers: IZ22–43, IZ23–38), in accordance with the Guidelines for Animal Experimentation of the Japanese Association for Laboratory Animal Science. All efforts were made to minimize suffering of the animals. Blood from 6–13 week-old C57/BL mice was drawn into heparinized syringes under sodium pentobarbital anesthesia. Unless otherwise stated, the blood was immediately mixed with 1/50 volume of 125 mM EDTA/EGTA. After centrifugation at 1,500× g at 4°C for 7 min, the supernatant was collected and used as freshly prepared plasma.
Determination of plasma concentrations of Nam, PRPP, ATP, and NMN
Plasma concentrations of Nam and NMN were determined by liquid chromatography/tandem mass spectrometry (LC/MS/MS) analysis. The fresh plasma was immediately mixed with an equal volume of 0.5 N perchloric acid (PCA). After centrifuging at 15,000× g for 5 min, supernatant was neutralized by adding an equal volume of 1 M ammonium formate (pH 6.4). The amounts of Nam and NMN in the supernatant were determined, using a triple quadrupole mass spectrometer (API3000, Applied Biosystems, Foster City, CA, USA), as described previously .
Plasma PRPP levels were determined by NAPRT assay as follows. The fresh plasma was immediately boiled for 60 sec, cooled on ice, and centrifuged. The supernatant (5–10 µl) was incubated with 20 µM [14C]NA (50 mCi/mmol), recombinant NAPRT (0.5 µg), 50 mM Tris-Cl− (pH 7.5), 10 mM MgCl2, 2.5 mM DTT, 1 mM ATP, and 1.5 µg BSA in a final volume of 30 µl. After incubating at 37°C for 15 min, the reaction was boiled for 60 sec and the amount of NaMN formed was determined using thin layer chromatography assay, as described above. A linear relationship was observed between the amount of PRPP added to the plasma (0.05–5 µM) and that of NaMN formed.
Plasma ATP levels were determined by luciferin/luciferase assay. The fresh plasma was immediately mixed with an equal volume of 0.5 N PCA. After centrifuging, supernatant was neutralized by ammonium formate and diluted 20-fold with H2O. The luciferin/luciferase mixture (430 µM luciferin, 8.6 µg/ml luciferase, 22 mM Tris-Cl− (pH 7.8), 8.6 mM MgSO4, 0.43 mM EDTA, 4.3 mM DTT, 86 µM sodium pyrophosphate, and 2.2 mg/ml BSA) was added to samples, and the sample luminescence was compared with an ATP standard curve.
Determination of degrading activity against PRPP, ATP, and NMN in the plasma
Fresh plasma prepared without the addition of EDTA/EGTA was incubated with PRPP, ATP, or NMN in the presence or absence of 2.5 mM EDTA/EGTA. After incubating at 4 or 37°C for the indicated times, the amounts of these phosphated compounds remaining in the plasma were determined, as described above.
In situ NAMPT reaction in the plasma
Fresh plasma (30 µl) prepared without the addition of EDTA/EGTA was incubated with recombinant NAMPT, PRPP, and ATP in a reaction mixture (40 µl) containing 50 mM Tris-Cl− (pH 7.5) at 37°C for 10 min. After the reaction was terminated by adding an equal volume of PCA, the NMN that formed was quantified, as described above.
ATP is an essential activator of NAMPT reaction
We first determined Km values for the substrates Nam and PRPP in the NAMPT reaction in the absence or presence of ATP. As shown in Table 1, Km values for Nam and PRPP dramatically decreased from 8.06 to 1.22 µM and from 23.2 to 0.51 µM, respectively, in the presence of 1 mM ATP. Taken together with the intracellular concentrations of Nam and PRPP (around 10 and 1 µM, respectively –), the kinetic data predicted that NAMPT would exhibit significant activity only in the presence of ATP under the intracellular condition. Indeed, when NAMPT was incubated with 20 µM Nam and 1 µM PRPP in the presence of 1 mM ATP, NMN formation was readily observed, whereas the enzyme did not exhibit significant activity without ATP (Table 2). In contrast, at much higher concentrations of Nam and PRPP (50 µM), the enzyme exhibited significant activity even in the absence of ATP (Table 2). These observations indicate that ATP is an essential activator for NAMPT at the intracellular concentrations of the substrates. As shown in Fig. 2, the millimolar levels of ATP were required for significant activity of NAMPT under the intracellular conditions. ADP, AMP, or NAD, each 1 mM in concentration, did not exhibit the stimulatory effect on NAMPT enzyme activity (data not shown). The similar requirement of ATP was observed for human NAPRT, the NAD biosynthetic enzyme also using PRPP as a substrate and ATP as an activator – (Tables 1 and 2, and Fig. 2). Replacing His-213 of NAPRT , which corresponds to His-219 in Salmonella typhimurium NAPRT that is the key amino acid responsible for activation by ATP , with Asn rendered the enzyme ATP-insensitive (Table 1).
NAMPT (A, 15 ng) and NAPRT (B, 20 ng) were incubated with 20 µM [14C]Nam and [14C]NA for 6 and 7 min, respectively, in the presence of 1 µM PRPP and indicated concentrations of ATP. The amounts of NMN (A) and NaMN (B) formed were determined. Data in figures 2 and 3 are representative of at least three experiments.
In mouse blood plasma, although Nam is present, PRPP and ATP are almost absent
We next investigated whether NAMPT exhibits in situ enzymatic activity in an extracellular environment, blood plasma, which has been reported to contain Nam  but little or no ATP . We determined concentrations of Nam, PRPP, and ATP in freshly prepared mouse blood plasma and evaluated NAMPT activity in the extracellular milieu, based on the kinetic parameters determined above. Using LC/MS/MS analysis  and the luciferin/luciferase method, we determined Nam and ATP concentrations as 4.6±1.5 µM (n = 3) and extremely low (1.3±0.3 µM, n = 3) in the plasma, respectively, which are consistent with those previously reported in mammalian circulation in general , . With NAPRT assay, plasma concentration of PRPP was determined as below the limit of detection (<50 nM, n = 3). In marked contrast with the previous report , NMN was not detected in the plasma (<50 nM, n = 5) by LC/MS/MS analysis.
It is well known that enzyme activities degrading phosphated compounds, including ATP, are present in blood . We might not detect PRPP, ATP, and NMN in blood plasma because they were rapidly degraded by the enzymes during the plasma preparation. To test this possibility, we examined the stability of PRPP, ATP, and NMN in the plasma. As shown in Fig. 3, these compounds were not significantly degraded in the plasma for at least 20 min in the presence of EDTA/EGTA at 4°C, the conditions used to prepare plasma. After incubating even at 37°C, they were largely protected from degradation (Fig. 3). In marked contrast, PRPP and ATP were rapidly degraded in the plasma without the addition of the chelators (Fig. 3). NMN was also degraded in the absence of the chelators at 37°C, but more slowly than PRPP or ATP (Fig. 3). These results indicate that although PRPP, ATP, and NMN are degraded in the plasma, these compounds are stable if plasma is maintained at 4°C in the presence of the chelators, and thus the inability to detect these compounds in the plasma is not due to their degradation during the plasma preparation.
PRPP, ATP, or NMN (150, 300, or 60 pmol, respectively) was incubated with the blood plasma (30 µl) in the presence of EDTA/EGTA at 4 (circles) or 37°C (triangles) or in the absence of the chelators at 37°C (squares) for the indicated times. After the incubation, the amounts of PRPP (A), ATP (B), and NMN (C) remaining at each time point in the plasma were determined and expressed as percent of those at 0 min.
From all these observations, we conclude that in the mouse blood plasma, although Nam is present, PRPP and ATP are almost absent. Taken together with much lower concentrations of Nam and PRPP in the plasma compared with their intracellular levels and the low affinity of NAMPT for the substrates in the absence of ATP, NAMPT should not efficiently catalyze its reaction in the plasma.
NAMPT does not form NMN in the blood plasma
To directly examine above notion, we incubated NAMPT with the plasma and the formation of NMN was determined. Even when NAMPT was incubated with the plasma at 25 µg/ml, a concentration 10 thousand times higher than those in blood plasma (1–3 ng/ml) , , NMN formation was not observed (n = 3). However, upon further addition of PRPP (30 µM) together with ATP (1 mM), a significant amount of NMN was synthesized in the reaction (0.42±0.07 µM, n = 3). When only PRPP (30 µM) was added to the plasma together with NAMPT, NMN formation was not observed (n = 3), confirming the essential requirement of ATP for the NAMPT reaction. Under the condition, PRPP remained in the plasma at 3.2±0.6 µM (n = 3). These observations indicate that NAMPT does not catalyze the NAMPT reaction in the plasma without the addition of both PRPP and ATP.
NAMPT is the rate-limiting enzyme catalyzing the first step of NAD salvage synthesis in mammalian cells . Also known as visfatin, circulating NAMPT has been reported to exert a variety of actions –, . It has been proposed that possible extracellular actions of visfatin are mediated through its NAMPT activity , , , . However, extracellular spaces are reported to contain little or no ATP . We thus questioned whether visfatin indeed catalyzes NMN formation under such extracellular milieus. To address this question, it is crucially important to evaluate the requirement of ATP for NAMPT under extra- as well as intracellular conditions. Using purified recombinant human NAMPT, we here demonstrated that ATP is an essential activator of NAMPT at physiological concentrations of the substrates PRPP and Nam.
Our kinetic analyses revealed that millimolar concentration of ATP increases the affinity of NAMPT for Nam and PRPP. In particular, Km value for PRPP was much higher than its intracellular concentration in the absence of ATP, whereas in the presence of 1 mM ATP, the Km value decreased to its intracellular concentration. Consistent with the kinetic data, NAMPT did not exhibit significant activity at intracellular concentrations of the substrates without ATP whereas the enzyme was dramatically activated in the presence of millimolar concentrations of ATP. In contrast, at sufficiently high concentrations of the substrates, NAMPT activity was essentially independent of the presence of ATP. These results indicate that millimolar levels of ATP are absolutely required for NAMPT to exhibit significant activity under intracellular milieu, whereas if much higher concentrations of the substrates are available, the nucleotide is not essential for the enzyme activity. Almost the same requirement of ATP was confirmed for human NAPRT. Mutagenesis study identified His-213 as a possible determinant of the activation of NAPRT by ATP. Recently, a similar effect of ATP on the NAMPT reaction has been reported by Burgos and Schramm .
We for the first time provided ATP concentrations that produce half-maximal stimulation (Ka) in NAMPT and NAPRT reactions under the physiological condition (Fig. 2). The obtained Ka values for ATP of NAMPT and NAPRT [341±63 µM (n = 5) and 395±91 µM (n = 3), respectively] were much higher than the reported Km values for ATP of human NMN/NaMN adenylyltransferase-1, -2, and -3 (59, 89, and 42 µM, respectively)  and NAD synthetase (89 µM) , the downstream enzymes in the NAD salvage synthesis  (Fig. 1). Comparison of these kinetic data revealed that NAMPT and NAPRT are the most sensitive enzymes to changes in cellular ATP levels in the salvage synthesis of NAD. Thus, it is likely that the synthesis of NAD is tightly regulated at the first steps of the pathway by the cellular concentration of ATP, and that based on the millimolar levels of normal cellular ATP this regulation may be significant during substantial depletion of ATP pools, such as that during cellular stress.
It has been hypothesized that visfatin acts as an extracellular NMN-forming enzyme and the resulting NMN is used for intracellular NAD biosynthesis after taken up by cells , , , . However, our study here provides three lines of evidence that do not support this hypothesis. Firstly, the essential requirement of ATP for NAMPT activity does not support NAMPT to catalyze NMN formation in the extracellular milieus. In mouse blood plasma, although the substrate Nam was present at a concentration of 4.6 µM, the other substrate PRPP was not detected and the activator ATP was almost absent (1.3 µM). Taken together with the low affinity of NAMPT for the substrates in the absence of the activator ATP as well as much lower concentrations of the substrates in the blood plasma compared with their intracellular levels, NAMPT should not efficiently catalyze its reaction in the plasma. Secondly, we found that PRPP is rapidly degraded in the plasma. Since the addition of EDTA/EGTA to the plasma inhibited the degradation of PRPP, alkaline phosphatases, with broad substrate specificity towards various phosphated compounds and requirement of metal ions for enzyme activity , may at least in part catalyze the degradation. The strong PRPP-degrading enzyme activity in the plasma, as well as the reported short half-life of ATP in the extracellular milieu , , confirmed in this study, excludes the possibility that extracellular concentrations of PRPP and ATP might rise high enough to support NMN synthesis, such as in the microenvironment of damaged cells. Thirdly, NAMPT added to the plasma did not catalyze NMN formation. The inability to detect NAMPT activity was not due to a small amount of the enzyme added or the inactivation of the enzyme in the plasma, since the enzyme was added to the plasma at a concentration 10 thousand times higher than those in blood plasma ,  and a significant amount of NMN was produced by the addition of PRPP and ATP. These results indicate that NAMPT did not catalyze its reaction in the plasma because of the extremely low concentrations of PRPP and ATP. Thus, NAMPT does not participate in NMN formation under such extracellular milieus. All three lines of evidence provided here indicate that extracellular visfatin can not be considered as an enzyme capable of synthesizing NMN.
We did not detect NMN in the plasma, even with a highly specific and sensitive LC/MS/MS method  that can quantify NMN if the mononucleotide is present at a concentration of at least 50 nM. The inability to detect NMN in the plasma is not due to its degradation during the plasma preparation because the nucleotide was stable under the conditions used to prepare plasma. In marked contrast with the present result, previous studies have reported NMN concentrations in blood plasma to be 80–90 µM  and culture medium of the muscle cells to be 300 µM , using HPLC analysis with UV absorbance detection. The reported high extracellular concentrations of NMN might be arisen from the difficulty of the quantification of NMN by HPLC analysis because of its extremely short elution time .
In conclusion, the essential requirement of ATP for NAMPT activity and the inability of NAMPT added to the mouse blood plasma to form NMN indicate that extracellular environments with little or no ATP do not allow extracellular visfatin to catalyze the in situ formation of NMN. In addition, extracellular NMN does not serve as a direct precursor of intracellular NAD biosynthesis . Collectively, these observations do not support the concept of “NAMPT-mediated systemic NAD biosynthesis” , . The presence of visfatin in circulation may merely be the result of cell death , or even if plasma visfatin has physiological functions it may act independent of its NMN biosynthetic activity . Our study would help to clarify physiological significance of extracellular NAMPT.
Conceived and designed the experiments: NH MT. Performed the experiments: NH KY TS. Analyzed the data: NH KY TS HO MT. Wrote the paper: NH MT.
- 1. Magni G, Amici A, Emanuelli M, Raffaelli N, Ruggieri S (1999) Enzymology of NAD+ synthesis. Adv Enzymol Relat Areas Mol Biol 73: 135–182.G. MagniA. AmiciM. EmanuelliN. RaffaelliS. Ruggieri1999Enzymology of NAD+ synthesis.Adv Enzymol Relat Areas Mol Biol73135182
- 2. Dietrich LS, Fuller L, Yero IL, Martinez L (1966) Nicotinamide mononucleotide pyrophosphorylase activity in animal tissues. J Biol Chem 241: 188–191.LS DietrichL. FullerIL YeroL. Martinez1966Nicotinamide mononucleotide pyrophosphorylase activity in animal tissues.J Biol Chem241188191
- 3. Elliott GC, Rechsteiner MC (1982) Evidence for a physiologically active nicotinamide phosphoribosyltransferase in cultured human fibroblasts. Biochem Biophys Res Commun 104: 996–1002.GC ElliottMC Rechsteiner1982Evidence for a physiologically active nicotinamide phosphoribosyltransferase in cultured human fibroblasts.Biochem Biophys Res Commun1049961002
- 4. Smith LD, Gholson RK (1969) Allosteric properties of bovine liver nicotinate phosphoribosyltransferase. J Biol Chem 244: 68–71.LD SmithRK Gholson1969Allosteric properties of bovine liver nicotinate phosphoribosyltransferase.J Biol Chem2446871
- 5. Niedel J, Dietrich LS (1973) Nicotinate phosphoribosyltransferase of human erythrocytes. PURIFICATION AND PROPERTIES. J Biol Chem 248: 3500–3505.J. NiedelLS Dietrich1973Nicotinate phosphoribosyltransferase of human erythrocytes. PURIFICATION AND PROPERTIES.J Biol Chem24835003505
- 6. Hayakawa T, Shibata K, Iwai K (1984) Nicotinate phosphoribosyltransferase from hog liver: Regulatory effect of ATP at physiological concentrations of 5-phosphoribosyl- 1-pyrophosphate. Agric Biol Chem 48: 455–460.T. HayakawaK. ShibataK. Iwai1984Nicotinate phosphoribosyltransferase from hog liver: Regulatory effect of ATP at physiological concentrations of 5-phosphoribosyl- 1-pyrophosphate.Agric Biol Chem48455460
- 7. Samal B, Sun Y, Stearns G, Xie C, Suggs S, et al. (1994) Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 14: 1431–1437.B. SamalY. SunG. StearnsC. XieS. Suggs1994Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor.Mol Cell Biol1414311437
- 8. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, et al. (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307: 426–430.A. FukuharaM. MatsudaM. NishizawaK. SegawaM. Tanaka2005Visfatin: a protein secreted by visceral fat that mimics the effects of insulin.Science307426430
- 9. Revollo JR, Körner A, Mills KF, Satoh A, Wang T, et al. (2007) Nampt/PBEF/Visfatin regulates insulin secretion in β cells as a systemic NAD biosynthetic enzyme. Cell Metab 6: 363–375.JR RevolloA. KörnerKF MillsA. SatohT. Wang2007Nampt/PBEF/Visfatin regulates insulin secretion in β cells as a systemic NAD biosynthetic enzyme.Cell Metab6363375
- 10. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, et al. (2007) Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 178: 1748–1758.AR MoschenA. KaserB. EnrichB. MosheimerM. Theurl2007Visfatin, an adipocytokine with proinflammatory and immunomodulating properties.J Immunol17817481758
- 11. Romacho T, Azcutia V, Vázquez-Bella M, Matesanz N, Cercas E, et al. (2009) Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia 52: 2455–2463.T. RomachoV. AzcutiaM. Vázquez-BellaN. MatesanzE. Cercas2009Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity.Diabetologia5224552463
- 12. Sommer G, Garten A, Petzold S, Beck-Sickinger AG, Blüher M, et al. (2008) Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine. Clin Sci 115: 13–23.G. SommerA. GartenS. PetzoldAG Beck-SickingerM. Blüher2008Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine.Clin Sci1151323
- 13. Garten A, Petzold S, Körner A, Imai S, Kiess W (2009) Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol Metab 20: 130–138.A. GartenS. PetzoldA. KörnerS. ImaiW. Kiess2009Nampt: linking NAD biology, metabolism and cancer.Trends Endocrinol Metab20130138
- 14. Imai S (2009) The NAD World: a new systemic regulatory network for metabolism and aging–Sirt1, systemic NAD biosynthesis, and their importance. Cell Biochem Biophys 53: 65–74.S. Imai2009The NAD World: a new systemic regulatory network for metabolism and aging–Sirt1, systemic NAD biosynthesis, and their importance.Cell Biochem Biophys536574
- 15. Wang P, Xu TY, Guan YF, Su DF, Fan GR, et al. (2009) Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc Res 81: 370–380.P. WangTY XuYF GuanDF SuGR Fan2009Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide.Cardiovasc Res81370380
- 16. Yegutkin GG (2008) Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade. Biochim Biophys Acta 1783: 673–694.GG Yegutkin2008Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade.Biochim Biophys Acta1783673694
- 17. Hara N, Yamada K, Shibata T, Osago H, Hashimoto T, et al. (2007) Elevation of cellular NAD levels by nicotinic acid and involvement of nicotinic acid phosphoribosyltransferase in human cells. J Biol Chem 282: 24574–24582.N. HaraK. YamadaT. ShibataH. OsagoT. Hashimoto2007Elevation of cellular NAD levels by nicotinic acid and involvement of nicotinic acid phosphoribosyltransferase in human cells.J Biol Chem2822457424582
- 18. Yamada K, Hara N, Shibata T, Osago H, Tsuchiya M (2006) The simultaneous measurement of nicotinamide adenine dinucleotide and related compounds by liquid chromatography/electrospray ionization tandem mass spectrometry. Anal Biochem 352: 282–285.K. YamadaN. HaraT. ShibataH. OsagoM. Tsuchiya2006The simultaneous measurement of nicotinamide adenine dinucleotide and related compounds by liquid chromatography/electrospray ionization tandem mass spectrometry.Anal Biochem352282285
- 19. Sauve AA, Moir RD, Schramm VL, Willis IM (2005) Chemical activation of Sir2-dependent silencing by relief of nicotinamide inhibition. Mol Cell 17: 595–601.AA SauveRD MoirVL SchrammIM Willis2005Chemical activation of Sir2-dependent silencing by relief of nicotinamide inhibition.Mol Cell17595601
- 20. Rosenbloom FM, Henderson JF, Caldwell IC, Kelley WN, Seegmiller JE (1968) Biochemical bases of accelerated purine biosynthesis de novo in human fibroblasts lacking hypoxanthine-guanine phosphoribosyltransferase. J Biol Chem 243: 1166–1173.FM RosenbloomJF HendersonIC CaldwellWN KelleyJE Seegmiller1968Biochemical bases of accelerated purine biosynthesis de novo in human fibroblasts lacking hypoxanthine-guanine phosphoribosyltransferase.J Biol Chem24311661173
- 21. Kawaguchi T, Veech RL, Uyeda K (2001) Regulation of energy metabolism in macrophages during hypoxia: ROLES OF FRUCTOSE 2, 6-BISPHOSPHATE and RIBOSE 1, 5-BISPHOSPHATE. J Biol Chem 276: 28554–28561.T. KawaguchiRL VeechK. Uyeda2001Regulation of energy metabolism in macrophages during hypoxia: ROLES OF FRUCTOSE 2, 6-BISPHOSPHATE and RIBOSE 1, 5-BISPHOSPHATE.J Biol Chem2762855428561
- 22. Gross J, Rajavel M, Segura E, Grubmeyer C (1996) Energy coupling in Salmonella typhimurium nicotinic acid phosphoribosyltransferase: Identification of His-219 as site of phosphorylation. Biochemistry 35: 3917–3924.J. GrossM. RajavelE. SeguraC. Grubmeyer1996Energy coupling in Salmonella typhimurium nicotinic acid phosphoribosyltransferase: Identification of His-219 as site of phosphorylation.Biochemistry3539173924
- 23. Catz P, Shinn W, Kapetanovic IM, Kim H, Kim M, et al. (2005) Simultaneous determination of myristyl nicotinate, nicotinic acid, and nicotinamide in rabbit plasma by liquid chromatography-tandem mass spectrometry using methyl ethyl ketone as a deproteinization solvent. J Chromatogr B 829: 123–135.P. CatzW. ShinnIM KapetanovicH. KimM. Kim2005Simultaneous determination of myristyl nicotinate, nicotinic acid, and nicotinamide in rabbit plasma by liquid chromatography-tandem mass spectrometry using methyl ethyl ketone as a deproteinization solvent.J Chromatogr B829123135
- 24. Körner A, Garten A, Blüher M, Tauscher R, Kratzsch J, et al. (2007) Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 92: 4783–4791.A. KörnerA. GartenM. BlüherR. TauscherJ. Kratzsch2007Molecular characteristics of serum visfatin and differential detection by immunoassays.J Clin Endocrinol Metab9247834791
- 25. Retnakaran R, Youn BS, Liu Y, Hanley AJ, Lee NS, et al. (2008) Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: a cross-sectional study. Clin Endocrinol 69: 885–893.R. RetnakaranBS YounY. LiuAJ HanleyNS Lee2008Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: a cross-sectional study.Clin Endocrinol69885893
- 26. Burgos ES, Schramm VL (2008) Weak coupling of ATP hydrolysis to the chemical equilibrium of human nicotinamide phosphoribosyltransferase. Biochemistry 47: 11086–11096.ES BurgosVL Schramm2008Weak coupling of ATP hydrolysis to the chemical equilibrium of human nicotinamide phosphoribosyltransferase.Biochemistry471108611096
- 27. Sorci L, Cimadamore F, Scotti S, Petrelli R, Cappellacci L, et al. (2007) Initial-rate kinetics of human NMN-adenylyltransferases: Substrate and metal ion specificity, inhibition by products and multisubstrate analogues, and isozyme contributions to NAD+ biosynthesis. Biochemistry 46: 4912–4922.L. SorciF. CimadamoreS. ScottiR. PetrelliL. Cappellacci2007Initial-rate kinetics of human NMN-adenylyltransferases: Substrate and metal ion specificity, inhibition by products and multisubstrate analogues, and isozyme contributions to NAD+ biosynthesis.Biochemistry4649124922
- 28. Hara N, Yamada K, Terashima M, Osago H, Shimoyama M, et al. (2003) Molecular identification of human glutamine- and ammonia-dependent NAD synthetases: Carbon-nitrogen hydrolase domain confers glutamine dependency. J Biol Chem 278: 10914–10921.N. HaraK. YamadaM. TerashimaH. OsagoM. Shimoyama2003Molecular identification of human glutamine- and ammonia-dependent NAD synthetases: Carbon-nitrogen hydrolase domain confers glutamine dependency.J Biol Chem2781091410921
- 29. Bours MJ, Swennen EL, Di Virgilio F, Cronstein BN, Dagnelie PC (2006) Adenosine 5′-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther 112: 358–404.MJ BoursEL SwennenF. Di VirgilioBN CronsteinPC Dagnelie2006Adenosine 5′-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation.Pharmacol Ther112358404
- 30. Formentini L, Moroni F, Chiarugi A (2009) Detection and pharmacological modulation of nicotinamide mononucleotide (NMN) in vitro and in vivo. Biochem Pharmacol 77: 1612–1620.L. FormentiniF. MoroniA. Chiarugi2009Detection and pharmacological modulation of nicotinamide mononucleotide (NMN) in vitro and in vivo.Biochem Pharmacol7716121620
- 31. Nikiforov A, Dölle C, Niere M, Ziegler M (2011) Pathways and subcellular compartmentation of NAD biosynthesis in human cells: FROM ENTRY OF EXTRACELLULAR PRECURSORS TO MITOCHONDRIAL NAD GENERATION. J Biol Chem 286: 21767–21778.A. NikiforovC. DölleM. NiereM. Ziegler2011Pathways and subcellular compartmentation of NAD biosynthesis in human cells: FROM ENTRY OF EXTRACELLULAR PRECURSORS TO MITOCHONDRIAL NAD GENERATION.J Biol Chem2862176721778
- 32. Stephens JM, Vidal-Puig AJ (2006) An update on visfatin/pre-B cell colony-enhancing factor, an ubiquitously expressed, illusive cytokine that is regulated in obesity. Curr Opin Lipidol 17: 128–131.JM StephensAJ Vidal-Puig2006An update on visfatin/pre-B cell colony-enhancing factor, an ubiquitously expressed, illusive cytokine that is regulated in obesity.Curr Opin Lipidol17128131
- 33. Li Y, Zhang Y, Dorweiler B, Cui D, Wang T, et al. (2008) Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism. J Biol Chem 283: 34833–34843.Y. LiY. ZhangB. DorweilerD. CuiT. Wang2008Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism.J Biol Chem2833483334843